NovoCure Limited · NASDAQ:NVCR
NovoCure — Investor Presentation (January 2019)
52 slides from NovoCure's investor presentation, January 2019
Slide 1: Novocure
Novocure updated January 2019
Slide 2: Forward-looking statements
forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology i
Slide 3: A global oncology company with a proprietary platform
a global oncology company with a proprietary platform 2 FDA-APPROVED 5 INDICATIONS 140+ ISSUED PATENTS INDICATIONS IN LATE-STAGE PIPELINE GLOBALLY $248M NET REVENUES >40% REVENUE GRWOTH $246M CASH FY 2018 2018 COMPARED TO 2017 ON HAND
Slide 4: 2018 key accomplishments
2018 key accomplishments ADVANCE OUR PIPELINE DRIVE OPTUNE ADOPTION • STELLAR mesothelioma data • >40% growth in prescriptions for presented and submitted to FDA for newly diagnosed GBM approval • $248M net revenues • First patient enrolled in PANOVA-3 • Collaboration with Zai Lab in China • HEPANOV
Slide 5: We can leverage physics to fight cancer
we can leverage physics to fight cancer AN ELECTRIC FIELD TUMOR TREATING FIELDS USES ELECTRIC FIELDS EXERTS FORCES ON CHARGED OBJECTS TO DISRUPT CELL DIVISION + + + + + + + + + + + + + + + - + + MISALIGNED TUBULINS ALTERNATING INTERFERE WITH ELECTRIC FIELDS - - - - - - - - - - - - - - - FORMATION OF
Slide 6: Single mechanism of action provides pipeline in a product
single mechanism of action provides pipeline in a product PRE-CLINICAL FIRST IN HUMAN CLINICAL FDA EVIDENCE EVIDENCE EVIDENCE APPROVAL Glioblastoma Brain metastases CANCERS Ependymoma OF THE CENTRAL Gliosarcoma NERVOUS Medulloblastoma SYSTEM Meningioma Mesothelioma Non-small cell lung cancer CANCERS
Slide 7: Drumbeat of clinical and regulatory milestones
drumbeat of clinical and regulatory milestones phase II pilot anticipated milestones milestones PANOVA data (1st cohort) PANOVA data (2nd cohort) HEPANOVA data INNOVATE data gastric trial data 2016 Today 2022 final EF-14 data LUNAR interim analysis INNOVATE-3 METIS data interim analysis STELLAR data
Slide 8: Proven to provide long-term quality survival to patients with newly diagnosed GBM
proven to provide long-term quality survival to patients with newly diagnosed GBM The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following m
Slide 9: With more time on Optune predicting survival benefit
with more time on Optune predicting survival benefit 86%of patients received a survival benefit from Optune because they used it more than half the time (n=388/450) TMZ, temozolomide * Based on amount of time Optune was turned on and providing therapy over the course of a month. This data reflects t
Slide 10: Higher energy at tumor bed predicted survival benefit
higher energy at tumor bed predicted survival benefit overall survival by energy delivered Higher energy* 25 months n=1221, p<0.01 Lower energy* 21 months n=1952 TMZ, temozolomide Dose density defined as a factor of both power loss density and monthly usage of therapy. * Higher energy defined as pow
Slide 11: Dose density = time on therapy x energy
dose density = time on therapy x energy overall survival by dose in newly diagnosed GBM higher energy* and 20-24 hours/day 37 months n=361 higher energy* and 18-20 hours/day 25 months n=442 higher energy* and <18 hours/day 23 months n=423 TMZ, temozolomide CI; confidence interval Dose density define
Slide 12: Potential to further improve efficacy via engineering
potential to further improve efficacy via engineering • Tumor Treating Fields effect is usage and energy dependent • EF-14 post-hoc analysis confirmed increased energy associated with improved overall survival • New algorithms developed to enable optimized treatment planning • Improved transducer ar
Slide 13: HDE application submitted to FDA for unresectable malignant pleural mesothelioma
HDE application submitted to FDA for unresectable malignant pleural mesothelioma (MPM) • Significant extension in overall survival versus historical control • 18.2 month median overall survival for Optune plus chemotherapy • 12.1 month median overall survival in historical control • No significant i
Slide 14: Established international presence
established international presence UNITED STATES EMEA † 29% 27% JAPAN 14% estimated penetration estimated penetration CHINA estimated penetration license agreement September 2018 † Considers Q4 2018 active markets: Germany, Austria, Israel and Switzerland Information above as of December 31, 2018. E
Slide 15: Track record of commercial execution
track record of commercial execution global net revenues (USD in thousands) $300,000 $250,000 $248,017 $248M FULL YEAR 2018 $200,000 $177,026 NET REVENUES $150,000 >40% $100,000 $82,888 $50,000 $33,087 $10,359 $15,490 REVENUE GROWTH 2018 COMPARED TO 2017 $0 2013 2014 2015 2016 2017 2018 See Novocure
Slide 16: Glioblastoma is tip of the iceberg
glioblastoma is tip of the iceberg potential to significantly expand total addressable market = 5,000 cases diagnosed annually in the U.S. Glioblastoma (GBM) Non-small cell lung cancer Mesothelioma (MPM) Pancreatic cancer Brain metastases from Ovarian cancer non-small cell lung cancer GBM ~1 ~3 ~5 T
Slide 17: Cash flow from GBM business largely funding R&D investments
cash flow from GBM business largely funding R&D investments $246M CASH ON HAND AT Steve is an Optune user Actor portrayal 2018 YEAR END Actor portrayal © Novocure 2019 17
Slide 18: Robust intellectual property portfolio
robust intellectual property portfolio INTELLECTUAL PROPERTY LAYERED PATENT STRATEGY • As of December 31, 2018 over • Hold fundamental IP for the use of alternating electric fields in oncology • Platform technology, tools and multiple applications covered, including 140 mechanism of action, use of a
Slide 19: Novocure is working to…
Novocure is working to… Advance our pipeline … extend Drive Optune adoption survival in some of the most Invest in our people and culture aggressive forms of cancer Create shareholder value © Novocure 2019 19
Slide 20: Optune indications for use and important safety information for GBM
Optune® indications for use and important safety information for GBM INDICATIONS • Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). • Optune with temozolomide is indicated for the treatment of adult patients
Slide 21: Optune indications for use and important safety information for GBM
Optune® indications for use and important safety information for GBM WARNINGS AND PRECAUTIONS • Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer). • Do not prescribe Optune for patients that ar
Slide 22: © Novocure 2019
novocure’ patientforward
Slide 23: Clinical appendix
clinical appendix © Novocure 2019 23
Slide 24: Tumor Treating Fields is frequency-tuned to cell size to maximize effects on mitosis
Tumor Treating Fields is frequency-tuned to cell size to maximize effects on mitosis EFFECTS ON CELLS ARE FREQUENCY SPECIFIC AND INVERSELY RELATED TO CELL SIZE Normal intestine Pancreatic Non-small cell lung Ovarian cancer Glioblastoma cancer cancer ~50 kHz 150 kHz 150 kHz 200 kHz 200 kHz © Novocure
Slide 25: Physical, observable mechanism of action
physical, observable mechanism of action CONTROL TUMOR TREATING FIELDS Blue staining is DAPI, highlighting DNA Red staining is for PH3, highlighting DNA binding proteins Green staining is for tubulin, highlighting the mitotic spindle Novocure data on file © Novocure 2019 25
Slide 26: Tumor Treating Fields induced severe spindle damage in cancer cell lines
Tumor Treating Fields induced severe spindle damage in cancer cell lines CONTROL TUMOR TREATING FIELDS A549 cells in lung tissue were treated with Tumor Treating Fields for 24 hours. Tubulin fluorescence images were inverted and pseudocolored so that increasing fluorescence intensity is indicated fr
Slide 27: Tumor Treating Fields resulted in abnormal chromosomal segregation
Tumor Treating Fields resulted in abnormal chromosomal segregation HYPODIPLOIDY AFTER TREATMENT TETRAPLOIDY AFTER TREATMENT A2780 cells were treated with TTFields for 96hours. Spectral karyotyping of A2780 cells Chromosome number was evaluated every 24hours. showing numerical aberrations Horizontal
Slide 28: Tumor Treating Fields may offer additive or synergistic benefits with chemotherapy
Tumor Treating Fields may offer additive or synergistic benefits in combination with chemotherapy A2780 OVCAR3 Caov-3 Combination of Tumor Treating Fields and paclitaxel chemotherapy Ovarian Cancer Cells were treated for 72 hr with paclitaxel alone (1–100 nM) and in combination with TTFields (2.7 V/
Slide 29: Tumor Treating Fields interfered with DNA damage response
Tumor Treating Fields interfered with DNA damage response Kim, E.H., et al. Oncotarget. 2016 Sep 20; 7(38): 62267–62279. TTF+IR triggers multinucleation and mitotic abnormalities in glioblastoma cells. Cells were exposed to 24 h of TTF, 5 Gy of γ-rays or 5 Gy of γ-rays followed by 24 h of TTF, indic
Slide 30: Tumor Treating Fields may inhibit metastases and activate an immune response
Tumor Treating Fields may inhibit metastases and activate an immune response CONTROL TUMOR TREATING FIELDS CONTROL TUMOR TREATING FIELDS Exemplary photos of surface lung metastases in Tumor Treating Fields treated Discrete intra-tumoral infiltration of CD45 positive T cells in control tumors and ver
Slide 31: Transducer array placement
transducer array placement abdominal torso pelvic array placement array placement array placement © Novocure 2019 31
Slide 32: Completed pilot STELLAR trial in mesothelioma
completed pilot STELLAR trial in mesothelioma A pilot, non-randomized, open-label study of Tumor Treating Fields (150 kHz) concomitant with pemetrexed and cisplatin or carboplatin in patients with previously untreated pleural mesothelioma • 80 patients with comparison to historical controls • Data p
Slide 33: STELLAR study design & patient characteristics
STELLAR study design & patient characteristics Unresectable malignant TTFields (150kHz, ≥ 18 h/day) + TTFields alone until Follow-up for pleural mesothelioma Pemetrexed/Cisplatin or Disease Progression survival N=80 Pemetrexed/Carboplatin x 6 The sample size provides 80% • Pemetrexed IV, 500 mg/m2 d
Slide 34: STELLAR efficacy results: primary endpoint met
STELLAR efficacy results: primary endpoint met Median OS (all pts) 18.2 months (95% CI 12.1-25.8) 1-year OS (all pts) 62.2% (95% CI 50.3%–72.0%) Median OS (epithelioid pts only) 21.2 months (95% CI 13.2-25.8) Median PFS 7.6 months (95% CI 6.7-8.6) mRECIST PR; DCR* [best response in 72 patients] 29 (
Slide 35: STELLAR safety results
STELLAR safety results Grade ≥3 AE Adverse event reported in >1 patient • Thirty-seven patients (46%) had TTFields- n (%) Patients with ≥1 AE, n(%) 21 (26) related skin toxicity Hematologic Disorders • Four patients (5%) had Grade 3 skin toxicity Anemia 6 (8) (rash or skin irritation) Leukopenia 3 (
Slide 36: Ongoing METIS trial in brain metastases
ongoing METIS trial in brain metastases A pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (150 kHz) for 1-10 brain metastases from non-small cell lung cancer • 270 patients randomized 1:1 • Tumor Treating Fields until second cerebral progression • Primary
Slide 37: Ongoing LUNAR trial in non-small cell lung cancer
ongoing LUNAR trial in non-small cell lung cancer A pivotal, randomized, open-label study of Tumor Treating Fields (150 kHz) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer following platinum failure • 540 patients randomized 1:1 • Primary endpoint – ov
Slide 38: Completed pilot EF-15 trial in lung cancer
completed pilot EF-15 trial in lung cancer A pilot, non-randomized, open-label study of Tumor Treating Fields (150 kHz) concomitant with pemetrexed in pretreated patients with locally advanced non-small cell lung cancer • 42 patients with comparison to historical controls • Data published in Lung Ca
Slide 39: Ongoing PANOVA-3 trial in pancreatic cancer
ongoing PANOVA-3 trial in pancreatic cancer A pivotal, randomized open-label study of Tumor Treating Fields (150 kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma • 556 patients randomized 1:1 • Tumor Treating Fields until loc
Slide 40: Completed pilot PANOVA trial in pancreatic cancer
completed pilot PANOVA trial in pancreatic cancer A pilot, double arm, non-randomized, open-label study of Tumor Treating Fields (150 kHz) concomitant with gemcitabine and nab-paclitaxel for frontline treatment of pancreatic adenocarcinoma • 40 patients (2 cohorts of 20 patients) with comparison to
Slide 41: Planned INNOVATE-3 trial in ovarian cancer
planned INNOVATE-3 trial in ovarian cancer A pivotal, randomized open-label study of Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer • 540 patients randomized 1:1 • Tumor Treating Fields until progression outside the abdomen/p
Slide 42: Completed pilot INNOVATE trial in ovarian cancer
completed pilot INNOVATE trial in ovarian cancer A pilot, non-randomized, open-label study of Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel in patients with recurrent ovarian cancer • 30 patients with comparison to historical controls • Data published in Gynecologic Oncology in
Slide 43: Ongoing HEPANOVA trial in liver cancer
ongoing HEPANOVA trial in liver cancer A phase 2 pilot trial of Tumor Treating Fields (150 kHz) concomitant with sorafenib for advanced hepatocellular carcinoma • 25 patients • Tumor Treating Fields until progressive disease per RECIST in the liver • Primary endpoint – overall radiological response
Slide 44: Additional presentation slides
additional presentation slides © Novocure 2019 44
Slide 45: Electric fields exert forces on electrically polarized molecules
electric fields exert forces on electrically polarized molecules © Novocure 2019 45
Slide 46: An electric field exerts forces on charged objects
an electric field exerts forces on charged objects + + + + + + + + + + + + + + + - + + - - - - - - - - - - - - - - - TUMOR TREATING FIELDS DESCRIBES ELECTRIC FIELDS THAT ALTERNATE 100,000 TO 300,000 TIMES PER SECOND TO TARGET CANCER CELLS © Novocure 2019 46
Slide 47: Tumor Treating Fields uses alternating electric fields to disrupt cell division
Tumor Treating Fields uses alternating electric fields to disrupt cell division MISALIGNED TUBULINS INTERFERE WITH FORMATION OF MITOTIC SPINDLE CANCER CELL DEATH © Novocure 2019 47
Slide 48: A portable, wearable device that delivers Tumor Treating Fields
a portable, wearable device that delivers Tumor Treating Fields ELECTRIC FIELD GENERATOR CONTINUOUS TREATMENT ALMOST ANYWHERE TRANSDUCER ARRAYS JB is an Optune user © Novocure 2019 48
Slide 49: The Optune system
the Optune® system ELECTRIC FIELD GENERATOR TRANSDUCER ARRAYS Portable Tumor Treating Fields generator Sterile, single-use transducer arrays replaced at least two times per week © Novocure 2019 49
Slide 50: Long-term, quality survival in newly diagnosed GBM
long-term, quality survival in newly diagnosed GBM The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and stand
Slide 51: Continued growth in active patients
continued growth in active patients active patients at period end 16 3,000 2,383 2,500 2,252 2,169 2,009 CONSECUTIVE QUARTERS 2,000 1,834 OF ACTIVE PATIENT GROWTH 1,683 SINCE INITIAL PRESENTATION 1,460 OF EF-14 DATA 1,500 1,266 1,091 985 10,000+ 891 1,000 797 605 425 468 500 372 PATIENTS TREATED TO
Slide 52: Robust intellectual property portfolio
robust intellectual property portfolio 140+ ISSUED PATENTS GLOBALLY AS OF DECEMBER 31, 2018 • Layered patent strategy • Expiration dates as late as 2036 • Numerous patents pending worldwide • PMA approval pathway © Novocure 2019 52